# CYSLTR2

Source: https://onco.cc/targets/cysltr2/  
OnCo record `cysltr2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CYSLTR2 (Cysteinyl leukotriene receptor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Uveal melanoma.

## Summary

Receptor for cysteinyl leukotrienes. The response is mediated via a G protein that activates a phosphatidylinositol-calcium second messenger system. Stimulation by BAY u9773, a partial agonist, induces specific contractions of pulmonary veins and might also have an indirect role in the relaxation of the pulmonary vascular endothelium.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Cervical Adenocarcinoma, Uveal Melanoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: cysteinyl leukotriene receptor 2; Cysteinyl leukotriene receptor 2; CysLT(2); CYSLT2R
- Tags: cancer-genes-wave
- Symbol: CYSLTR2
- Class: tumor-suppressor
- Biology: Receptor for cysteinyl leukotrienes. The response is mediated via a G protein that activates a phosphatidylinositol-calcium second messenger system. Stimulation by BAY u9773, a partial agonist, induces specific contractions of pulmonary veins and might also have an indirect role in the relaxation of the pulmonary vascular endothelium. The rank order of affinities for the leukotrienes is LTC4 = LTD4 >> LTE4. Location: Cell membrane (UniProt). Locus 13q14.2 (HGNC).
- Where found: Cervical cancer: IntOGen driver in 1 cohort (CEAD); Uveal melanoma: IntOGen driver in 1 cohort (UM)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:18274: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18274
- UniProt Q9NS75: https://www.uniprot.org/uniprotkb/Q9NS75/entry
- NCBI Gene 57105: https://www.ncbi.nlm.nih.gov/gene/57105
- Ensembl ENSG00000152207: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152207

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)

---
JSON: https://onco.cc/api/v1/entities/cysltr2.json